Form 4: Century Therapeutics Insider Sells Shares

Century Therapeutics President and CEO Brent Pfeiffenberger reported a transaction involving common stock on May 15, 2026.

Summary

• Brent Pfeiffenberger, President and CEO of Century Therapeutics, reported a transaction on May 15, 2026.
• This transaction involved the withholding of 31,172 shares of common stock by the Issuer to satisfy tax obligations related to the vesting of restricted stock units.
• Following this transaction, Mr. Pfeiffenberger beneficially owns 3,679,786 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transaction is a routine event related to executive compensation and tax obligations, rather than a discretionary sale of stock.

Negatives

• Insider selling can sometimes be interpreted as a negative signal by the market, although in this case it is related to tax withholding obligations upon vesting of restricted stock units.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and are closely watched by investors to gauge management's confidence in the company. The specific nature of this transaction, related to tax withholding, is a common occurrence upon the vesting of equity awards.

Stakeholder Impact

• Shareholders: The transaction itself is a standard tax-related event and is unlikely to have a direct material impact on the share price. However, any insider selling, even for tax reasons, can be subject to market interpretation.

Key Dates

Keywords

SEC Form 4, Insider Transaction, Century Therapeutics, Brent Pfeiffenberger, Common Stock, Restricted Stock Units, Tax Withholding